FILE:FMC/FMC-8K-20050307135416.txt.gz
EVENTS:	Regulation FD Disclosure
TEXT:
ITEM: Regulation FD Disclosure
 
 
 
 
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
 
 
 
 
 
On March 7, 2005, Thomas C. Deas Jr., Vice President and Treasurer was a speaker at the "Citigroup 14
th
Annual High Yield/Leveraged Finance Conference" in which he presented an overview of FMC Corporation. Slides used in his presentation at the conference are included herein as an exhibit. These slides may also be accessed at the company's website (www.fmc.com) and will be available for a period of at least thirty days.
 
This report is not deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
Date: March 7, 2005
 
 
 
 

Exhibit 99.1
 
FMC Corporation
Citigroup 14th Annual High Yield / Leveraged Finance Conference
March 7, 2004
Thomas C. Deas, Jr. Vice President & Treasurer
 
Disclaimer
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
These slides and the accompanying presentation contain "forward-looking statements" that represent management's best judgment as of the date hereof based on information currently available. Actual results of the Company may differ materially from those contained in the forward-looking statements.
Additional information concerning factors that may cause results to differ materially from those in the forward-looking statements is contained in the Company's periodic reports filed under the Securities Exchange Act of 1934, as amended.
The Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.
Non-GAAP Financial Terms
These slides contain certain "non-GAAP financial terms" which are defined in the appendix. In addition, we have provided reconciliations of non-GAAP terms to the closest GAAP term in the appendix.
1
 
FMC Corporation
Diversified chemical company with leading market positions in industrial, consumer and agricultural markets globally
($million, 12/31/04)
FMC
Revenue: $2,051.2
EBITDA: $369.8
Margin*: 18.0%
Industrial Specialty Agricultural
Chemicals Chemicals Products
Revenue: $813.7 Revenue: $538.0 Revenue: $703.5
EBITDA: $124.3 EBITDA: $128.5 EBITDA: $147.7
Margin*: 15.3% Margin*: 23.9% Margin*: 21.0%
* EBITDA margin
2
 
Company Strengths
Leading market positions
Global presence
Diversified business mix and high-quality customer base
Diversified and integrated cost structure
Focused R&D and strong applications expertise
Commitment to strong credit profile
3
 
Leading Market Positions
Product Market Position
Soda Ash #1 in N.A.
Industrial Hydrogen Peroxide #1 in N.A.
Chemicals Phosphorus Chemicals (1) #2 in N.A. (2)
Persulfates #1 in N.A.
Pyrethroids #2 in N.A.
Agricultural
Products Carbofuran #1 Globally
Microcrystalline Cellulose #1 Globally
Specialty Carrageenan #1 Globally
Chemicals
Alginates #2 Globally
Lithium Specialties #1 Globally (1)
(1) Shared
(2) Held by Astaris, our 50%-owned joint venture
4
 
Global Presence
Geographically diversified business
Latin America 17%
Asia Pacific 11%
Europe, Middle East & Africa 29%
North America 43%
Note: Based on 2004 consolidated sales
5
 
Diversified Customers and End Markets
Revenues by End Market
Other 16%
Chemicals 6%
Cyclical 19%
Pulp & Paper 4%
Glass/Fiberglass 4%
Electronics 2% Other 3%
Agricultural 33%
Detergents 10%
Pharmaceuticals 11%
Food 8%
Bottle Glass 3%
Non-Cyclical 81%
Approximately 80% of sales are to non-cyclical end markets Long-term relationships with blue chip customers No one customer represents more than 5% of sales
Top 10 customers in aggregate make up approximately 15% of sales
Note: Based on 2003 consolidated sales
6
 
Diversified and Integrated Cost Structure
Low-cost sourcing of raw materials
Backward integration: soda ash, lithium
Global sourcing of renewable resources: pulp, seaweed
Low reliance on purchased raw materials
Total raw materials represent approximately 25% of cost of sales
Limited use of petrochemical feedstock reduces volatility of raw material costs
No single raw material represents more than 7% of total raw material purchases
Low energy demand requirements
Energy costs represent approximately 10% of cost of sales
7
 
Focused R&D and Applications Expertise
Agricultural Products
Focused insecticide discovery strategy that combines whole insect screening with biochemical, target-based testing
Use of state-of-the-art technologies including genomics, robotics and advanced computational software
Specialty Chemicals
BioPolymer focus on developing close working relationship with large food and pharmaceutical companies' R&D groups
Lithium focus on new compounds used in the chemical synthesis of active pharmaceutical ingredients and energy storage
Industrial Chemicals
Process R&D focused entirely on continued cost leadership
8
 
Our Objectives
Unlocking value and creating a faster growing FMC
Realize the operating leverage inherent within FMC
Sustained double-digit growth in earnings*
Industrial Chemicals recovery
Continued growth in Specialty Chemicals and Agricultural Products
Create greater financial flexibility
Reduce net debt to $600 million by the end of 2006
Regain an investment grade credit rating
Focus the portfolio on higher growth businesses
Manage Specialty Chemicals and Agricultural Products for growth
Manage Industrial Chemicals for cash
Divest any business that cannot sustain our cost of capital
Improve ROIC to 12 percent minimum by 2006
* Before restructuring and other income and charges
9
 
Industrial Chemicals
10
 
Industrial Chemicals Overview
2004 Consolidated Sales: $813.7 million
Asia 7%
North America 50%
Latin America 8%
Europe/Middle East/Africa 36%
Alkali (Soda ash) 47%
Peroxygens 18%
Foret 35%
Excludes phosphorus chemicals sales at Astaris JV, largely in North America
#1 North American manufacturer of soda ash and peroxygens Backward integration into natural resources Low-cost, proprietary process technology
11
 
Industrial Chemicals 2005 Outlook
Expected to be main driver of FMC's earnings growth in near term
2005 earnings to be up approximately 50 percent versus 2004
2005 total price realization of $50 million
Successful price increase on domestic non-restricted soda ash volume Significant improvement in soda ash export prices Peroxide price increase of a couple cents per lb.
Higher selling prices for North American and European phosphates Peak soda ash prices expected by 2006-7
Partially offset by cost increases of $25 million
Freight and energy account for 2/3's of the increase Balance is raw materials: caustic, sulfuric acid, acetic acid, phosphate rock
Increased volumes and fixed cost reduction to contribute
12
 
Industrial Chemicals Performance
Now emerging from 2003 trough profits that were more than $100 million below the late 1990's peak
Millions $250 $200 $150 $100 $50 $0 $194 $208 $177 $133 $130 $94 $124
25% 20% 15% 10% 5% 0%
Margin
1998 1999 2000 2001 2002 2003 2004
EBITDA Capital Spending EBITDA Margin (%)
13
 
Soda Ash Demand
North American Soda Ash Shipments
12 10 8 6 4 2 0
Export
Glass Container Flat Glass
Chemicals Detergents
Other
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005F
Demand Drivers:
GDP
Cost advantage of natural soda ash versus synthetic soda ash Industrialization rates in key export markets
14
 
U.S. Soda Ash Supply & Cost Positions
Share of Nameplate Capacity
OCI General Solvay Wyoming Solvay Colorado SVM
29% 20% 17% 19% 6% 9%
Cost Index Base = Solution Mining
1.6
1.2
0.8
0.4
0
FMC Solution Mining
FMC Longwall Mining
Competitors
15
 
Sold-out U.S. Soda Ash Industry
2005 domestic price increase is the most significant since 1996
U.S. Bulk
Soda Ash Price Index (1990 = 1.0)
1.2 1.1 1 0.9 0.8
100% 95% 90% 85%
U.S. Capacity Utilization (% Effective)
1990 1991
1992
1993 1994
1995
1996 1997
1998
1999
2000
2001
2002
2003
2005F 2004
2005 Contract Renewals Price Index Effective Capacity Util.
16
 
Tight Domestic Hydrogen Peroxide Market
2005 to represent the third consecutive year of rising prices
Hydrogen Peroxide Price Index (1994=1.0)
1.2 1.1 1 0.9 0.8 0.7 0.6
100 95 90 85 80 75 70
Effective Capacity Utilization (%, North America)
1994
1995 1996
1997
1998
1999
2000 2001
2002
2003 2004
2005F
Price Index Effective Capacity Util.
17
 
Specialty Chemicals
18
 
Specialty Chemicals Overview
2004 Consolidated Sales: $538.0 million
Asia 15%
North America 41%
Latin America 8%
Europe/Middle East/Africa 36%
BioPolymer 72%
Lithium 28%
BioPolymer:
Adds structure, texture and stability to food
Acts as a binder & disintegrant for dry tablet drugs
Market leader in every product line
Lithium:
One of two global, integrated manufacturers
Focus on specialty productspharmaceuticals and energy storage devices
19
 
Specialty Chemicals Performance
The benefit of continued sales growth has recently been offset by cost pressures in BioPolymer
Millions $140 $120 $100 $80 $60 $40 $20 $0 $127 $122 $116 $132 $129
30% 25% 20% 15% 10% 5% 0%
Margin
2000 2001 2002 2003 2004
EBITDA Capital Spending EBITDA Margin (%)
20
 
Specialty Chemicals 2005 Outlook
Expected to be the long-term driver of top and bottom line growth
2005 revenue growth in mid-single digits
Strong organic growth in BioPolymer end-markets of 3-6% per year
Focus on lithium specialty markets growing at 4 to >10% per year
Selective increases in selling prices
Earnings growth rate in excess of revenue growth
Productivity improvements to drive margin expansion in 2005
Raw materials to remain stable versus 2004 and improve thereafter
Promising new products for the future
Oral-dosage-form technologies
Functional food ingredients
Fine chemistry applications of lithium
21
 
Agricultural Products
22
 
Agricultural Products Overview
2004 Consolidated Sales: $703.5 million
Asia 13%
North America 35%
Latin America 36%
Europe Middle East Africa 16%
Insecticides 73%
Fungicides 2%
Herbicides 25%
Proprietary, branded insecticides and herbicides
Key crops: cotton, corn, rice, cereals, fruits and vegetables FMC differentiated by:
Focused innovation (R&D is ~10% of sales)
Cost reduction strategies
The depth and breadth of partnerships and alliances
23
 
Agricultural Products Performance
Significant recovery driven by improving global farm economy, strength in Brazil and benefits of a highly focused FMC strategy
Millions $160 $140 $120 $100 $80 $60 $40 $20 $0 $114 $101 $99 $111 $148
25% 20% 15% 10% 5% 0%
Margin
2000 2001 2002 2003 2004
EBITDA Capital Spending EBITDA Margin (%)
24
 
Agricultural Products 2005 Outlook
Expected to remain strong near-term and benefit from in-licensed products in the next several years
elatively flat revenue versus 2004
Growth in new products and labels in the Americas and Europe
Brazilian market to remain strong for at least another year
Unfavorable impact of price pressure from generic producers in North American insecticides
Similar earnings in 2005 versus 2004
Relatively flat sales
Continued progress in reducing manufacturing costs via outsourcing
Higher energy, raw material and freight costs
In-licensed products to contribute $50-90 million to sales by 09
25
 
Financial Overview
26
 
Strong 2004 Results
Outstanding performance in Agricultural Products
A 10% year-over-year increase in sales
Even stronger earnings growth of 44%
Healthy pipeline of in-licensed and newly discovered compounds
Improvement in Industrial Chemicals
Generally higher North American selling prices
Significant growth in soda ash export volumes
$20 million in annual restructuring savings at Astaris
Sold-out market conditions in several businesses
Steady top-line growth in our Specialty Chemicals franchise
Steady growth in demand for BioPolymer and Lithium
Several unfavorable one-time cost impacts in 2004
Unfavorable raw material costs
Reduction in net debt of $155 million
27
 
Multi-Year Recovery
We remain on track to deliver a sustained multi-year recovery in sales and earnings
2,200 2,000 1,800
1,600 1,400
1,200
1,000
Sales, $ millions
6.00 5.00 4.00
3.00 2.00
1.00
-
EPS*, $
2000 2001 2002 2003 2004 2005E
Sales EPS
* Earnings before restructuring and other income and charges per diluted share; calculated in 2005E using the mid-point of January 28, 2005 guidance.
28
 
Contingent Obligation Update
Legacy contingent obligations have largely been addressed
As-of 2001 YE Current
Astaris Keepwell Payments $111.9 million* $- **
TG Soda Ash Payment*** $75 million $
FTI Guarantees 289 million $4 million
Note: * Reflects 50% of Astaris' total debt at 12/31/01
** Keepwell obligation ended February 2005
*** TG Soda Ash final payment of $32.4 million made on 12/31/03
29
 
Credit Statistics
12/31/2004
EBITDA $370
Interest Expense, net 78
Capital Expenditures 85
Debt (1) 893
Debt / EBITDA 2.4x
EBITDA / Interest Exp. 4.7x
(EBITDACapEx) / Interest Exp. 3.7x
1) Long-term debt plus current portion of long-term debt.
30
 
Capital Structure
12/31/2002 12/31/2003 12/31/2004
($ - millions)
Debt
$250 Term Loan Due 2007 245.1 243.6 -
$100 Term Loan Due 2009 - - 100.0
$400 million Revolving Credit Agreement - - -
10.25% Notes Due 2009 350.7 351.4 352.0
Industrial Revenue & Pollution Control Bonds 220.6 218.7 218.2
Other Public Domestic Debt 386.3 222.7 222.8
Short-term Debt 64.3 13.8 30.2
Total Debt $ 1,267.0 $ 1,050.2 $ 923.2
Cash
Restricted Cash 274.6 136.9 9.7
Cash 89.6 57.0 212.4
Total Cash $ 364.2 $ 193.9 $ 222.1
Net Debt $ 902.8 $ 856.3 $ 701.1
Stockholders' Equity $ 406.0 $ 588.3 $ 876.2
Total Capital (Total Debt + Stockholders' Equity) $ 1,673.0 $ 1,638.5 $ 1,799.4
Net Debt/Total Capital, less all cash 69.0% 59.3% 44.4%
31
 
Lengthened Maturities
Our successful refinancing in 2004 of our bank facilities addressed our maturity profile $ - millions $450 $400 $350 $300 $250 $200 $150 $100 $50 $0 $1 $70 $10 $63 $88 $417 $248
2004 2005 2006 2007 2008 2009 2010+
32
 
Summary
Great businesses, each generating EBITDA of over $100 million
Industrial Chemicals earnings still $75 million below peak
Steady growth in Ag Products & Specialty Low capital expenditure requirements Significant improvement in creditworthiness
33
 
FMC Corporation
 
Non-GAAP Financial Terms
These slides contain certain "non-GAAP financial terms" which are defined below. In addition, we have provided reconciliations of non-GAAP terms to the closest GAAP term in the appendix of this presentation.
EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is the sum of Income (loss) from continuing operations before income taxes and Depreciation and Amortization.
EBITDA Margin is the quotient of EBITDA (defined above) divided by Revenue.
ROIC (Return on Invested Capital) is the sum of Earnings from continuing operations before restructuring and other income and charges and after-tax Interest expense divided by the sum of Short-term debt, Current portion of long-term debt, Long-term debt and Total shareholders' equity.
35
 
Segment Financial Terms
These slides contain references to segment financial items which are presented in detail in Note 19 of FMC's 2003 Form 10-K. Some of the segment financial terms are "non-GAAP financial terms" and are defined below. In addition, we have provided reconciliations of non-GAAP terms to the closest GAAP term in the appendix of this presentation.
EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) for a segment is the sum of Income (loss) from continuing operations before income taxes for that segment and Depreciation and Amortization for that segment.
EBITDA Margin for a segment is the quotient of EBITDA (defined above) divided by Revenue for that segment.
36
 
Appendix: Earnings Reconciliation
RECONCILIATION OF NET INCOME (GAAP) TO AFTER-TAX INCOME FROM CONTINUING OPERATIONS, EXCLUDING RESTRUCTURING AND OTHER INCOME AND CHARGES (NON-GAAP) (Unaudited, in millions, except per share amounts)
Twelve Months Ended
December 31,
2004 2003
Diluted earnings per common share (GAAP) $4.28 $0.75
Discontinued operations per diluted share (GAAP) 0.42 0.37
Restructuring and other charges per diluted share, before tax* 0.40 1.35
Tax effect of restructuring and other charges per diluted share (0.16) (0.57)
Write-off of deferred financing fees per diluted share** 0.26 -
Tax effect of write-off of deferred financing fees per diluted share (0.10) -
Tax adjustments per diluted share*** (1.90) -
Diluted after-tax income from continuing operations per share,
excluding restructuring and other income and charges (Non-GAAP) $3.20 $1.90
Average number of shares used in diluted
after-tax income from continuing operations per share computations 37.4 35.6
*Restructuring and other charges includes FMC's share of charges recorded by Astaris, LLC, the phosphorous joint venture. FMC's share of such charges are included in "Equity in loss of affiliates" and were $0.7 million-gain and $11.5 million, before tax, for the three and twelve months ended December 31, 2004 and $8.4 million and $53.3 million, before tax, for the three and twelve months ended December 31, 2003 respectively.
**In conjunction with entering into the 2004 Credit Agreement on October 29, 2004, the Company wrote off $9.9 million of deferred financing fees associated with the previous credit agreements.
***For the three months ended December 31, 2004, tax adjustments represent a tax benefit of $38.6 million resulting from an adjustment to income tax liabilities due to a December 2004 pronouncement from the Internal Revenue Service and a tax benefit of $31.1 million primarily related to valuation allowance adjustments. For the twelve months ended December 31, 2004, tax adjustments includes the items noted in the three months ended December 31, 2004 as well as a tax benefit of $1.3 million resulting from a refund received from the Internal Revenue Service.
37
 
Appendix: EBITDA Reconciliation
Reconciliation of full-year 2004 consolidated income from continuing operations before income taxes (a GAAP measure) to 2004 EBITDA (a Non-GAAP measure)
(Unaudited, in millions)
12/31/2004
Income (loss) from continuing operations before income taxes $131.1
Add:
Restructuring and other charges 15.0
Interest expense, net 78.4
Write-off of deferred financing fees 9.9
Affiliate Interest Expense 1.1
Depreciation and amortization 134.3
EBITDA (Non-GAAP) 369.8
38
 
Appendix: Segment EBITDA Reconciliation
Reconciliation of full-year 2004 segment operating profit (a GAAP measure) to 2004 EBITDA (a Non-GAAP measure)
(Unaudited, in millions)
Industrial Specialty Agricultural
Segment Chemicals Chemicals Products
FY 2004 segment operating profit (GAAP) $57.3 $96.1 $118.4
Add:
Depreciation and amortization 67.0 32.4 29.3
FY 2004 EBITDA (Non-GAAP) $124.3 128.5 $ 147.7
39
 
Appendix: ROIC Reconciliation
Reconciliation of Numerator Income from Continuing Operations (GAAP) to numerator Income from Continuing Operations before restructuring and other income and charges and and after-tax interest expense, net (Non-GAAP) used in ROIC (Return on Invested Capital) calculation.
(Unaudited, in millions)
2003 2004
Actual Actual
Income (loss) from continuing operations (GAAP) $39.8 $175.6
Interest Expense, net 92.2 78.4
Tax effect of Interest Expense, net (20.0) (18.2)
Restructuring and other charges* 48.2 15.0
Tax effect of restructuring and other charges (gains) (20.5) (5.8)
Write-off of deferred financing fees** 9.9
Tax effect of write-off of deferred financing fees (3.9)
Tax Adjustments*** (71.0)
ROIC numerator (Non-GAAP) $139.7 $180.0
2-Point Average Denominator Dec-02 Dec-03 Dec-04
Short-term Debt $64.3 $13.8 $30.2
Current portion of long-term debt 166.8 3.0 70.8
Long-term debt 1,035.9 1,033.4 822.2
Shareholder's Equity 406.0 588.3 876.2
$1,673.0 $1,638.5 $1,799.4
ROIC denominator (2 pt. avg) (GAAP) $1,655.8 $1,719.0
ROIC ( Using Non-GAAP Numerator) 8.4% 10.5%
*Restructuring and other charges includes FMC's share of charges recorded by Astaris, LLC, the phosphorous joint venture. FMC's share of such charges are included in "Equity in loss of affiliates" and were $0.7 million-gain and $11.5 million, before tax, for the three and twelve months ended December 31, 2004 and $8.4 million and $53.3 million, before tax, for the three and twelve months ended December 31, 2003 respectively.
**In conjunction with entering into the 2004 Credit Agreement on October 29, 2004, the Company wrote off $9.9 million of deferred financing fees associated with the previous credit agreements.
***For the three months ended December 31, 2004, tax adjustments represent a tax benefit of $38.6 million resulting from an adjustment to income tax liabilities due to a December 2004 pronouncement from the Internal Revenue Service and a tax benefit of $31.1 million primarily related to valuation allowance adjustments. For the twelve months ended December 31, 2004, tax adjustments includes the items noted in the three months ended December 31, 2004 as well as a tax benefit of $1.3 million resulting from a refund received from the Internal Revenue Service.
40
 
FMC Corporation


